IAVI 004

Principal Investigator(s):
Objective:Evaluate an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected, healthy Kenyan male and female volunteers at low risk for HIV infection
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionVolunteers will be screened up to 4 weeks before entry, will receive two doses of 5 x 10^7 pfu MVA.HIVA intradermally at 4 week intervals, and will be followed up for 189 days after the first immunization. Additional follow-up visits at 12 and 18 months after the first immunization will be scheduled.
Mode of DeliveryIntradermal
Official Code: IAVI 004
Trial Sponsors: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH)
Start Date
End Date
Age range: ↔ any
Population:Cisgender Men, Cisgender Women